单分子阵列检测血清IFN-α2与干燥综合征系统性疾病表现相关
本研究采用Simoa超敏免疫分析检测pSS、SLE、SSc及健康对照的血清IFN-α2,发现pSS患者IFN-α2水平显著高于健康对照但低于SLE,且与血液ISG表达正相关,可高准确度识别高ISG表达的pSS患者,提示Simoa法可用于患者分层。
要点
- pSS患者血清IFN-α2中位数61.3 fg/ml,显著高于健康对照(≤5 fg/ml)和SSc(11.6 fg/ml)。
- 血清IFN-α2与血液ISG表达正相关(r=0.66-0.94),识别高ISG表达pSS的AUC为0.90。
- 自身抗体、IgG、HCQ治疗、皮肤病变及腺外表现史与pSS血清IFN-α2独立相关。
核心结论
- Simoa检测的血清IFN-α2可反映pSS、SLE和SSc的血液ISG表达。
- Simoa法有望用于IFN靶向治疗的患者分层或历史队列回顾性分析。
研究设计与样本
- 检测pSS(n=85和n=110)、SLE(n=24)、SSc(n=23)及健康对照(n=68)的血清IFN-α2。
- 采用Simoa IFN-α assay在HD-X分析仪上检测,并以IFN-I报告基因 assay和全血ISG(IFI44、IFI44L、IFIT1、IFIT3、MxA)RT-PCR或MxA蛋白ELISA评估IFN-I通路活化。
主要发现
- pSS患者血清IFN-α2中位数61.3 fg/ml,高于健康对照(中位数≤5 fg/ml,P<0.001)和SSc(中位数11.6 fg/ml,P=0.043)。
- pSS患者血清IFN-α2低于SLE(中位数313.5 fg/ml,P=0.068)。
- 血清IFN-α2与血液ISG表达正相关(r=0.66-0.94,P<0.001)。
- Simoa IFN-α2识别高ISG表达pSS的AUC为0.90,特异性80-93%,敏感性71-84%;MxA ELISA的AUC为0.93。
- 在独立pSS队列盲法验证中获得 comparable accuracy。
关键数值与推荐
- pSS患者血清IFN-α2中位数61.3 fg/ml,健康对照中位数≤5 fg/ml,SSc中位数11.6 fg/ml,SLE中位数313.5 fg/ml。
- 血清IFN-α2与血液ISG表达相关系数r=0.66-0.94(P<0.001)。
- Simoa IFN-α2识别高ISG表达pSS的AUC 0.90,特异性80-93%,敏感性71-84%。
临床怎么用
- 血清IFN-α2检测可作为pSS患者IFN-I通路活化的替代标志物,用于识别高ISG表达亚群。
- 在IFN靶向治疗背景下,Simoa法可能有助于患者分层或历史队列的回顾性分析。
局限性
- 原文未明确报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Type I IFN (IFN-I) activation is a prominent feature of primary SS (pSS), SLE and SSc. Ultrasensitive single-molecule array (Simoa) technology has facilitated the measurement of subfemtomolar concentrations of IFNs. Here we aimed to measure IFN-α2 in serum from pSS, SLE and SSc using a Simoa immunoassay and correlate these levels to blood IFN-stimulated gene (ISG) expression and disease activity. METHODS: Serum IFN-α2 was measured in patients with pSS (n = 85 and n = 110), SLE (n = 24) and SSc (n = 23) and healthy controls (HCs; n = 68) using an IFN-α Simoa assay on an HD-X analyser. IFN-I pathway activation was additionally determined from serum by an IFN-I reporter assay and paired samples of whole blood ISG expression of IFI44, IFI44L, IFIT1, IFIT3 and MxA by RT-PCR or myxovirus resistance protein 1 (MxA) protein ELISA. RESULTS: Serum IFN-α2 levels were elevated in pSS (median 61.3 fg/ml) compared with HCs (median ≤5 fg/ml, P < 0.001) and SSc (median 11.6 fg/ml, P = 0.043), lower compared with SLE (median 313.5 fg/ml, P = 0.068) and positively correlated with blood ISG expression (r = 0.66-0.94, P < 0.001). Comparable to MxA ELISA [area under the curve (AUC) 0.93], IFN-α2 measurement using Simoa identified pSS with high ISG expression (AUC 0.90) with 80-93% specificity and 71-84% sensitivity. Blinded validation in an independent pSS cohort yielded a comparable accuracy. Multiple regression indicated independent associations of autoantibodies, IgG, HCQ treatment, cutaneous disease and a history of extraglandular manifestations with serum IFN-α2 concentrations in pSS. CONCLUSION: Simoa serum IFN-α2 reflects blood ISG expression in pSS, SLE and SSc. In light of IFN-targeting treatments, Simoa could potentially be applied for patient stratification or retrospective analysis of historical cohorts.
引用
- Huijser E, Göpfert J, Brkic Z, et al. Serum interferon-α2 measured by single-molecule array associates with systemic disease manifestations in Sjögren's syndrome. Rheumatology (Oxford). 2022. PMID: 34505866. doi:10.1093/rheumatology/keab688
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。